Analysts Set Glaukos Corporation (NYSE:GKOS) PT at $117.23

Shares of Glaukos Corporation (NYSE:GKOS) have received an average rating of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $119.9231.

GKOS has been the topic of several research reports. Wells Fargo & Company lifted their price target on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Citigroup raised their target price on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. upped their price target on shares of Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. UBS Group increased their price target on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Finally, BTIG Research restated a “buy” rating and set a $116.00 price objective on shares of Glaukos in a research report on Friday, January 2nd.

Glaukos Trading Down 0.9%

Shares of GKOS opened at $113.09 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos has a 52-week low of $73.16 and a 52-week high of $163.71. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of -73.44 and a beta of 0.67. The business’s fifty day moving average is $104.56 and its 200-day moving average is $95.18.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same period last year, the firm posted ($0.28) earnings per share. Glaukos’s revenue was up 38.1% compared to the same quarter last year. Equities analysts anticipate that Glaukos will post -1.08 EPS for the current fiscal year.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 315 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the transaction, the chief financial officer owned 50,488 shares of the company’s stock, valued at $5,301,240. This represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at approximately $8,312,940. This represents a 17.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 24,655 shares of company stock worth $2,310,025. Insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its stake in shares of Glaukos by 460.8% in the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after purchasing an additional 49,492 shares during the last quarter. Assenagon Asset Management S.A. lifted its holdings in Glaukos by 15.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 182,393 shares of the medical instruments supplier’s stock valued at $20,594,000 after buying an additional 24,848 shares during the period. Diversified Trust Co. boosted its position in Glaukos by 72.6% during the fourth quarter. Diversified Trust Co. now owns 7,252 shares of the medical instruments supplier’s stock valued at $819,000 after acquiring an additional 3,050 shares during the last quarter. Swiss Life Asset Management Ltd acquired a new stake in Glaukos during the 3rd quarter worth about $209,000. Finally, JPMorgan Chase & Co. grew its holdings in Glaukos by 4.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock worth $54,645,000 after acquiring an additional 27,646 shares during the period. Institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.